<DOC>
	<DOCNO>NCT00770159</DOCNO>
	<brief_summary>This study ass safety , tolerability , PK , PD weekly dose MK0822 healthy postmenopausal woman .</brief_summary>
	<brief_title>A Study Test Once-Weekly Doses Odanacatib ( MK0822 ) Healthy Adult Females ( 0822-005 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Subject less equal 75 year age Subject postmenopausal female Subject within 30 % ideal body weight Subject judge good health Subject nonsmoker Subject willing avoid excessive alcohol consumption duration study Subject willing avoid strenuous physical activity duration study Subject agree refrain consume grapefruit grapefruit juice duration study Subject history multiple/severe allergy foods drug Subject surgery within 12 week start study give blood within 4 week start study Subject history major GI abnormalities/ulcers , genitourinary , cardiovascular , hepatic , pulmonary , psychiatric , endocrine , metabolic disease Subject history bone disease treatment bisphosphonates Subject infection/condition would suppress immune system , include HIV Subject history chronic/active hepatic ( liver ) disease , include Hepatitis B C Subject regularly us illegal drug Subject consumes 3 alcoholic beverage per day Subject consume 4 cup brew coffee ( equivalent caffeinated beverage ) per day Subject require use prescription nonprescription medication study Part I : subject receive treatment follow : estrogen preparation , anabolic steroid , calcitonin , progestin within 6 month study start ; thyroid hormone stable dose ; fluoride treatment great 1mg/day 2 week ; Glucocorticoid treatment ; Vitamin A great 10,000 U/day , vitamin D great 2000 U/day , anticonvulsant ; selective estrogen receptor modulators within 6 month study start ; parathyroid hormone within 2 year study start ; bisphosphonates .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>